Related references
Note: Only part of the references are listed.Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
Tatsushi Kodama et al.
CANCER LETTERS (2014)
Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive Lymphoma Patients
Carlo Gambacorti Passerini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib
Sai-Hong Ignatius Ou et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
Luc Friboulet et al.
CANCER DISCOVERY (2014)
Insight into Crizotinib Resistance Mechanisms Caused by Three Mutations in ALK Tyrosine Kinase using Free Energy Calculation Approaches
Huiyong Sun et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2013)
Acquired Resistance to Crizotinib from a Mutation in CD74-ROS1
Mark M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK
Hui-Yong Sun et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Crizotinib for ALK-Rearranged Non-Small Cell Lung Cancer: A New Targeted Therapy for a New Target
Leena Gandhi et al.
CLINICAL CANCER RESEARCH (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
Johannes M. Heuckmann et al.
CLINICAL CANCER RESEARCH (2012)
Inhibitors of the anaplastic lymphoma kinase
Luca Mologni
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Anaplastic Lymphoma Kinase Aberrations in Rhabdomyosarcoma: Clinical and Prognostic Implications
J. Carlijn van Gaal et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
Doron Lipson et al.
NATURE MEDICINE (2012)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Takaaki Sasaki et al.
CANCER RESEARCH (2011)
Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene
Avaniyapuram Kannan Murugan et al.
CANCER RESEARCH (2011)
Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum
Larisa V. Debelenko et al.
MODERN PATHOLOGY (2011)
Crizotinib in Anaplastic Large-Cell Lymphoma
Carlo Gambacorti-Passerini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
ALK-positive extramedullary plasmacytoma with expression of the CLTC-ALK fusion transcript
Wei-ya Wang et al.
PATHOLOGY RESEARCH AND PRACTICE (2011)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Young Lim Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
Sara Redaelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers
Eva Lin et al.
MOLECULAR CANCER RESEARCH (2009)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma
Xiao-Li Du et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2007)
Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer
Pablo Perez-Pinera et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer
Ferdous Rastgar Jazii et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient
E Tamborini et al.
GASTROENTEROLOGY (2004)
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL
M Azam et al.
CELL (2003)
Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines
WG Dirks et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Expression of the ALK tyrosine kinase gene in neuroblastoma
L Lamant et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
